01:54:37

Working Session - Accelerate Study and Natural History Study

29:26

Final Working Session

01:10:35

SJIA Lung Disease Cytokine Plasticity Hypothesis - Peter Nigrovic & Bruce Binstadt

01:09:23

Searching for Historical Control for Refractory SJIA Trials

33:46

Patient Perspective for Lung Disease in SJIA

17:21

Summary of Challenges in Refractory SJIA Trials - Rashmi Sinha

15:40

Lung Ultrasound to track lung disease in SJIA LD Patients - Patricia Vega

38:47

The Role of External Controls in FDA Decision Making - Veronica Miller

44:46

Retrospective Natural History Study in SJIA & MAS

44:08

How to include refractory SJIA w/out arthritis in Clinical Trials?

58:07

How to overcome barriers to MAS Clinical Trials?

59:00

It is Time for IL18 Driven Clinical Trials

22:15

Real World Evidence for Rare Disease Clinical Trials - Isaac Kohane

49:37

The Elephant in the Room SJIA Diagnostic/Classification Criteria

20:30

Unmet Needs and Patients Stories

53:41

Working Session - SJIA Diagnostic Criteria and IL18 Trials

13:01

Distinct Clinical Phenotypes in Refractory SJIA & MAS - Alexei Grom

01:42:12

BMT in Refractory SJIA-Lung Disease

09:00

A Lifetime with SJIA - Nicole Dalton

20:16

The Many Faces of Refractory SJIA - Parent Panel

25:42

MAS: Old and New Treatments - Scott Canna

21:16

What is Stills Disease and Strategies for Treatment - Petros Efthimiou

18:58

What is SJIA and Strategies for Treatment: Alexei Grom

17:58

Some Interesting SJIA-LD Cases from around the world

21:25

SJIA-LD Research Updates: Vivan Saper

14:12

SJIA-LD Research Updates: Grant Schulert

18:41

SJIA LD Research Update - Adriana Almeida De Jesus

14:05

SJIA-LD Research Updates: Scott Canna

42:35

Global Perspecitves on Treating SJIA

29:46

Bridging the Gap Between SJIA and Still's

36:29

Treating Refractory SJIA and MAS

01:08:30

SJIA-LD Treatment Strategies QA

40:04

Panel Discussion: What do we know about SJIA-LD

41:41

COVID-19 in SJIA & Other Rheumatic Patients

02:15:42

Challenges in Drug Development for SJIA, Still’s & MAS

19:32

Patients with recurrent MAS & liver involvement - Kate & Jonathan Pierce & Zulayka Martinez

35:27

Understanding the patient experience of SJIA-LD

11:48

Pathology in MAS Liver patients - Alexei Grom & Fabrizio DeBenedetti

14:34

Is Emapalumab relevant for SJIA-LD patients - Fabrizio DeBenedetti

43:11

SJIA LD Panel - Rae Yeung, Raphaela Goldbach Masnky, Alexei Grom, Stewart Levine

24:50

Jak inhibitors Panel - Adriana de Jesus, Massimo Gadina & Fabrizio DeBenedetti

21:01

Alveolar Macrophage Dysfunction in Lung Disease - Stewart Levine

30:11

Review of biomarkers; IL18 as a biomarker and a target - Dr. Scott Canna

31:05

Report from Grom & Schulert labs about SJIA-LD - Dr. Alexei Grom

27:01

Learnings from Cincinnati SJIA-LD patient cohort - Grant Schulert

28:40

An overview of selective Jak inhibitors and relevance for SJIA-LD - Dr. Massimo Gadina

10:35

SJIA Foundation Mission - Rashmi Sinha

07:30

SJIA Foundation Community - Leah Bush

31:50

What we Know About Lung Disease in SJIA - Grant Schulert

06:01

How the SJIA Foundation Plans to Reach every SJIA Family - Phil Reardon

24:08

Treating Infections in the Context of Inflammation & Immunosuppression - Lara Danziger-Isakov

17:33

Research Powered by the Family Day Sample Collection - Alexei Grom

27:37

Expert Panel - Ask Anything about SJIA & MAS

21:43

Introduction to SJIA - Jennifer Huggins

24:15

Impaired Growth: Lessons from Crohns - Lee Denson

33:11

New Drugs for SJIA & MAS - Fabrizio DeBenedetti

03:43

Setting the Stage for Discussion of MAS & Lung Disease - Alexei Grom

21:14

Cell based therapies in sJIA - Nora Singer

08:48

IL6 Updates - Fabrizio DeBenedetti

38:09

Ella's Story - Perspectives on sJIA treatment - Frank Giamie